Molbio Diagnostics IPO

Molbio Diagnostics IPO closed on 12 Aug 2026. Allotment 13 Aug 2026, listing 17 Aug 2026. Price band ₹768–₹807, lot 18 shares, GMP +₹120 (14.87%). Track allotment on Allotly.

About Molbio Diagnostics

Molbio Diagnostics is a point-of-care diagnostics company that develops and manufactures healthcare technologies for diagnosing infectious and non-communicable diseases. The company’s core business revolves around its proprietary ‘Truenat’ platform, a portable, battery-operated polymerase chain reaction (PCR) system designed for use in resource-limited settings. This platform provides rapid and accurate test results within approximately one hour. The company’s primary source of revenue is the sale of its ‘Truenat’ devices and the recurring sale of compatible, disease-specific micro-PCR test kits. Molbio offers a wide range of tests for various infectious diseases, including tuberculosis, COVID-19, Hepatitis B and C, HIV, and HPV. Through its subsidiaries, the company also provides devices related to radiology and digital pathology.

Strengths

• Proprietary TruNAT platform enables rapid, point-of-care molecular diagnostics.
• Strong footprint in government and public health procurement programs.
• Wide disease coverage including TB, COVID-19, HIV, hepatitis and HPV.
• In-house R&D supported by integrated manufacturing capabilities.
• Global presence with products deployed across multiple countries.

Risks

• Heavy dependence on government and international aid agency funding.
• High revenue concentration from tuberculosis-related test kits.
• A limited number of large customers contribute a significant share of revenues.
• Regulatory delays may impact the commercialisation of new diagnostic tests.
• Demand fluctuations are linked to public health policies and funding cycles.

See all IPOs · Apply for your family on Allotly